Patients with Ischemic Heart Disease who will undergo PCI
Conditions
Interventions
Following determination of lipid levels at baseline, rosuvastatin 5 mg will be given once daily for 7 days prior to PCI and 14 days after PCI regardless of baseline levels. Administration of lipid-low
100 mg/dL in accordance with the 2002 JAS Guidelines for the Diagnosis and Treatment of Arteriosclerotic Cardiovascular Diseases
Following determination of lipid levels at baseline, a placebo will be
100 mg/dL in accordance with the 2002 JAS Guidelines for the Diagnosis and Treatment of Arteriosclerotic Cardiovascular Diseases
Sponsors
Department of Cardiovascular Medicine Kyushu University Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients untreated with statin for at least 2 weeks who will undergo PCI
Exclusion criteria
Exclusion criteria: Cases that requires emergent revascularization such as STEMI. Cases with grave complications such as pulmonary edema or cardiogenic shock. Cases with severe hyperlipidemia such as familial hypercholesterolemia who should be treated with statin. High risk cases for rhabdomyolysis such as hypothyroidism or taking fibrates. Pregnant or nursing female cases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurence of postprocedural increase of CK-MB >2 times above the upper normal limit or increase of troponin-T above the upper normal limit. Occurence of re-elevation of those factors as for cases with baseline elevation | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurence of all major adverse cardiac events (death, acute myocardial infarction, unplanned cardiac catheterization a/o revascularization, hospitalization due to worsened angina) from the time of entry to 6 months of follow-up | — |
Countries
Japan
Contacts
Public ContactKoji Todaka
Kyushu University Hospital Department of Cardiovascular Medicine
Outcome results
None listed